

Please Enter

/D. Margaret Seaman/

14 April 2010

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature

Date

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:	Konstantinos Gavardinas	Group Art Unit: 1625
Serial No.:	10/598,330	Examiner: D. Seaman
Application Date:	August 24, 2006	Conf No.: 2716
For:	Bicyclic Substituted Indole-Derivative Steroid Hormone Nuclear Receptor Modulators	
Docket No.:	X-16125	

AMENDMENT UNDER 37 C.F.R. 1.312

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Introductory Comments

In response to the Notice of Allowance dated January 14, 2010, please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.

Amendments to the Specification

Please replace the paragraph that appears at page 49, line 29 – page 50, line 2 of the present application with the following paragraph, marked up to reflect the changes made.

Unless otherwise indicated, ^1H NMR spectra are recorded on a Varian Mercury 400 MHz Nuclear Magnetic Resonance (NMR) spectrometer at ambient temperature. Data are reported as follows: chemical shift (δ) in ppm from internal standard tetramethylsilane, multiplicity (b = broad, s = singlet, d = doublet, t = triplet, m = multiplet), and integration. Liquid chromatography-mass spectrometry (LC-MS) data were obtained on an Agilent 1100 Series LC/MSD instrument.

Remarks

Pursuant to a telephone message from the Examiner, received on April 5, 2010, a typographical error has been identified in the present application. Specifically, the symbol "□" appears at page 49, line 31 of the specification. Applicants have amended the specification by replacing the "□" symbol with the delta symbol "δ".

Applicants respectfully submit that one of ordinary skill in the art would appreciate this error as a typographical mistake. In support of the correct symbol, Applicants direct the Examiner to the Preparations and Examples contained in the specification which clearly use the term "δ" in relation to NMR data chemical shifts (see for example, Preparations 1-5 and Examples 2 and 4). Thus, Applicants respectfully submit that present amendment contains no added matter.

Applicants courteously request entry of this amendment, which is being submitted in conjunction with the payment of the issue fee, and passage of the present application to allowance.

Respectfully submitted,

/Alexander Wilson/
Alexander Wilson
Attorney for Applicants
Registration No. 45,782
Phone: 317-277-0190

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

April 13, 2010